- Home
- ELTX vs OPNW Comparison
ELTX vs OPNW Comparison
Compare ELTX & OPNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELTX | OPNW |
|---|---|---|
| Founded | 2011 | 2023 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.3M | 74.3M |
| IPO Year | 2014 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ELTX | OPNW |
|---|---|---|
| Price | $1.90 | $1.65 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $13.67 | N/A |
| AVG Volume (30 Days) | ★ 258.8K | 58.0K |
| Earning Date | 11-12-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,301,000.00 | ★ $16,398,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.44 | $1.79 |
| 52 Week High | $16.00 | $6.69 |
Technical Indicators
Market Signals| Indicator | ELTX | OPNW |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 16.62 |
| Support Level | $1.74 | N/A |
| Resistance Level | $1.97 | $6.69 |
| Average True Range (ATR) | 0.15 | 0.56 |
| MACD | 0.04 | -0.28 |
| Stochastic Oscillator | 79.63 | 0.20 |
Price Performance
Historical ComparisonAbout ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.